Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Lung Neoplasms × 1-phenyl-3,3-dimethyltriazene × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Carcinoma, Basal Cell 7 Carcinoma, Non-Small-Cell Lung 5 Squamous Cell Carcinoma of Head and Neck 4 Pancreatic Neoplasms 3 Keratosis, Actinic 3 Cholangiocarcinoma 3 Tongue Neoplasms 2 Pleural Diseases 2 Non-Muscle Invasive Bladder Neoplasms 2 Mycosis Fungoides 2 Mesothelioma, Malignant 2 Carcinoma, Transitional Cell 2 Bile Duct Neoplasms 2 Basal Cell Nevus Syndrome 2 Uterine Cervical Neoplasms 1 Uterine Cervical Dysplasia 1 Thyroid Neoplasms 1 Thyroid Cancer, Papillary 1 Stomatitis 1 Skin Neoplasms 1 Sezary Syndrome 1 Salivary Gland Neoplasms 1 Prostatic Neoplasms 1 Photosensitivity Disorders 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Pain 1 Neoplasms 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoid Interstitial Pneumonia 1 Lung Neoplasms 1

Interventions

Carboplatin 301 Cisplatin 220 Radiotherapy 188 Paclitaxel 179 Pemetrexed 168 Docetaxel 157 Gemcitabine 140 pembrolizumab 132 Erlotinib Hydrochloride 100 Magnetic Resonance Spectroscopy 92 Etoposide 89 Bevacizumab 79 Specimen Handling 75 durvalumab 68 Nivolumab 66 Radiosurgery 64 Drug Therapy 55 Blood Specimen Collection 51 Vinorelbine 50 osimertinib 48 Gefitinib 42 Surveys and Questionnaires 40 Biopsy 40 atezolizumab 37 Radiation 37 Irinotecan 37 Topotecan 35 Cyclophosphamide 35 Standard of Care 34 Surgical Procedures, Operative 31

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01842555 2018-08-24

PDT Registry

Main Line Health

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡